Small interfering RNA for cancer treatment: overcoming hurdles in delivery

In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Charbe, Nitin Bharat, Amnerkar, Nikhil D., Ramesh, B., Tambuwala, Murtaza M., Bakshi, Hamid A., Aljabali, Alaa A.A., Khadse, Saurabh C., Satheeshkumar, Rajendran, Satija, Saurabh, Metha, Meenu, Chellappan, Dinesh Kumar, Shrivastava, Garima, Gupta, Gaurav, Negi, Poonam, Dua, Kamal, Zacconi, Flavia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714980/
https://www.ncbi.nlm.nih.gov/pubmed/33304780
http://dx.doi.org/10.1016/j.apsb.2020.10.005
Descripción
Sumario:In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.

Ejemplares similares